Liposome-encapsulated anthraquinone improves efficacy and safety in triple negative breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Liposome-encapsulated anthraquinone improves efficacy and safety in triple negative breast cancer

Published:2022-02 Issue: Volume:342 Page:31-43
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

George Thomashire A.,Chen Max M.,Czosseck Andreas,Chen Hsiang-Pei,Huang Hsu-Shan,Lundy David J.

Funder

Taipei Medical University

Schlumberger Foundation

Republic of China Ministry of Science and Technology

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference63 articles.

1. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018

2. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease;Bianchini;Nat. Rev. Clin. Oncol.,2016

3. Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype;Gerratana;Cancer Treat. Rev.,2018

4. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet.,2014

5. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes;Carey;Clin. Cancer Res.,2007

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Efficiency of Liposome-Entrapped Iridium(III) Complexes Inhibiting Tumor Growth In Vitro and In Vivo;Journal of Medicinal Chemistry;2024-09-12

2. The mechanisms of nanoparticle delivery to solid tumours;Nature Reviews Bioengineering;2024-02-08

3. Recent advances and clinical translation of liposomal delivery systems in cancer therapy;European Journal of Pharmaceutical Sciences;2024-02

4. Engineering of Amphiphilic Erlotinib Analogue as Novel Nanomedicine for Non-Small Cell Lung Cancer Therapy;International Journal of Nanomedicine;2023-11

5. Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer;Journal of Drug Targeting;2023-08-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3